Sundry Photography/iStock Editorial via Getty Images BioMarin Pharmaceutical ( NASDAQ: BMRN ) unveiled a major leadership shakeup on Wednesday, appointing a new business chief and a new head of Research & Development. Accordingly, Greg Friberg will join as Executive Vice President and Chief Research & Development Officer on Sept. 30, replacing Hank Fuchs, BioMarin’s ( BMRN ) current R&D head, who is retiring after 15 years at the company.
Friberg joins BMRN from Amgen ( AMGN ), where he served as the pharma giant’s head of medical affairs, overseeing its rare disease business. Meanwhile, former Cytokinetics ( CYTK ) CEO James Sabry has been appointed as the company’s Executive Vice President and Chief Business Officer, effective Oct. 7.
BMRN said Sabry, who currently serves as Global Head of Partnering at Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ), has led 1,200 transactions throughout his career. In conjunction with his appointment, Brinda Balakrishnan, head of BioMarin’s ( BMRN ) Corporate Strategy and Business Development, has decided to leave the company, effective Oct. 1.
Meanwhile, Fuchs will continue to serve the company in an advisory capacity through March 3, 2025. More on BioMarin Pharmaceutical BioMarin Pharmaceutical Inc. (BMRN) Q2 2024 Earnings Call Transcript BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024 BioMarin Pharmaceutical upgraded to Outperform ahead of investor day Piper lists eight defensive biotechs to face market vol.